Recent advances in neuroblastoma

Kanika Bowen-Jallow, Dai H. Chung

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Although there have been recent advances with multimodal therapy, treatment of neuroblastoma remains a clinical challenge. Despite the identification of several genetic features, there has not been a significant increase in 5-year survival in the last decade. This review will highlight the current operative strategies along with new research developments aimed at improving survival. RECENT FINDINGS: The goal of surgical intervention in the early stages of neuroblastoma is complete curative resection. In advanced-stage disease, tissue biopsy for staging is the initial goal. In recent years, minimally invasive surgery (MIS) is considered in carefully selected patients. Recent advances in neuroblastoma research have focused on tyrosine kinase inhibition, differentiation, pathway inhibition, and immunotherapy. Several of these targets have shown promising results in vivo and are currently under investigation for potential clinical trials. SUMMARY: New information on the importance of cell signaling and the targeting of specific genes of interest are providing key insights into neuroblastoma. Only through the discovery of novel treatment strategies made available through the advancement of research will neuroblastoma be survivable for patients with advanced-stage disease.

Original languageEnglish (US)
Pages (from-to)350-356
Number of pages7
JournalCurrent Opinion in Pediatrics
Volume21
Issue number3
DOIs
StatePublished - Jun 2009

Fingerprint

Neuroblastoma
Research
Combined Modality Therapy
Minimally Invasive Surgical Procedures
Survival
Gene Targeting
Protein-Tyrosine Kinases
Immunotherapy
Clinical Trials
Biopsy
Therapeutics

Keywords

  • Gastrin-releasing peptide
  • MYCN
  • Neuroblastoma
  • Phosphatidylinositol 3-kinase

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Recent advances in neuroblastoma. / Bowen-Jallow, Kanika; Chung, Dai H.

In: Current Opinion in Pediatrics, Vol. 21, No. 3, 06.2009, p. 350-356.

Research output: Contribution to journalReview article

Bowen-Jallow, Kanika ; Chung, Dai H. / Recent advances in neuroblastoma. In: Current Opinion in Pediatrics. 2009 ; Vol. 21, No. 3. pp. 350-356.
@article{0f098fedc0794bdc98e67ab88b86fcb9,
title = "Recent advances in neuroblastoma",
abstract = "PURPOSE OF REVIEW: Although there have been recent advances with multimodal therapy, treatment of neuroblastoma remains a clinical challenge. Despite the identification of several genetic features, there has not been a significant increase in 5-year survival in the last decade. This review will highlight the current operative strategies along with new research developments aimed at improving survival. RECENT FINDINGS: The goal of surgical intervention in the early stages of neuroblastoma is complete curative resection. In advanced-stage disease, tissue biopsy for staging is the initial goal. In recent years, minimally invasive surgery (MIS) is considered in carefully selected patients. Recent advances in neuroblastoma research have focused on tyrosine kinase inhibition, differentiation, pathway inhibition, and immunotherapy. Several of these targets have shown promising results in vivo and are currently under investigation for potential clinical trials. SUMMARY: New information on the importance of cell signaling and the targeting of specific genes of interest are providing key insights into neuroblastoma. Only through the discovery of novel treatment strategies made available through the advancement of research will neuroblastoma be survivable for patients with advanced-stage disease.",
keywords = "Gastrin-releasing peptide, MYCN, Neuroblastoma, Phosphatidylinositol 3-kinase",
author = "Kanika Bowen-Jallow and Chung, {Dai H.}",
year = "2009",
month = "6",
doi = "10.1097/MOP.0b013e32832b1240",
language = "English (US)",
volume = "21",
pages = "350--356",
journal = "Current Opinion in Pediatrics",
issn = "1040-8703",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Recent advances in neuroblastoma

AU - Bowen-Jallow, Kanika

AU - Chung, Dai H.

PY - 2009/6

Y1 - 2009/6

N2 - PURPOSE OF REVIEW: Although there have been recent advances with multimodal therapy, treatment of neuroblastoma remains a clinical challenge. Despite the identification of several genetic features, there has not been a significant increase in 5-year survival in the last decade. This review will highlight the current operative strategies along with new research developments aimed at improving survival. RECENT FINDINGS: The goal of surgical intervention in the early stages of neuroblastoma is complete curative resection. In advanced-stage disease, tissue biopsy for staging is the initial goal. In recent years, minimally invasive surgery (MIS) is considered in carefully selected patients. Recent advances in neuroblastoma research have focused on tyrosine kinase inhibition, differentiation, pathway inhibition, and immunotherapy. Several of these targets have shown promising results in vivo and are currently under investigation for potential clinical trials. SUMMARY: New information on the importance of cell signaling and the targeting of specific genes of interest are providing key insights into neuroblastoma. Only through the discovery of novel treatment strategies made available through the advancement of research will neuroblastoma be survivable for patients with advanced-stage disease.

AB - PURPOSE OF REVIEW: Although there have been recent advances with multimodal therapy, treatment of neuroblastoma remains a clinical challenge. Despite the identification of several genetic features, there has not been a significant increase in 5-year survival in the last decade. This review will highlight the current operative strategies along with new research developments aimed at improving survival. RECENT FINDINGS: The goal of surgical intervention in the early stages of neuroblastoma is complete curative resection. In advanced-stage disease, tissue biopsy for staging is the initial goal. In recent years, minimally invasive surgery (MIS) is considered in carefully selected patients. Recent advances in neuroblastoma research have focused on tyrosine kinase inhibition, differentiation, pathway inhibition, and immunotherapy. Several of these targets have shown promising results in vivo and are currently under investigation for potential clinical trials. SUMMARY: New information on the importance of cell signaling and the targeting of specific genes of interest are providing key insights into neuroblastoma. Only through the discovery of novel treatment strategies made available through the advancement of research will neuroblastoma be survivable for patients with advanced-stage disease.

KW - Gastrin-releasing peptide

KW - MYCN

KW - Neuroblastoma

KW - Phosphatidylinositol 3-kinase

UR - http://www.scopus.com/inward/record.url?scp=67651092243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651092243&partnerID=8YFLogxK

U2 - 10.1097/MOP.0b013e32832b1240

DO - 10.1097/MOP.0b013e32832b1240

M3 - Review article

C2 - 19381091

AN - SCOPUS:67651092243

VL - 21

SP - 350

EP - 356

JO - Current Opinion in Pediatrics

JF - Current Opinion in Pediatrics

SN - 1040-8703

IS - 3

ER -